What FDA QSR and ISO 13485 Harmonization Means

In its proposed rule, the FDA admits that “regulatory expectations for a QMS have evolved since the current Part 820 was implemented over 20 years ago,” and that, “By proposing to incorporate ISO 13485 by reference, we are seeking to explicitly require current internationally recognized regulatory expectations for QMS for devices subject to FDA’s jurisdiction.”

If you’re not ISO 13485-certified
If you’re based in the U.S. and currently only following the QSR, you might want to pursue ISO 13485 certification as harmonization approaches. At the very least, you should spend some time comparing 21 CFR Part 820 with ISO 13485:2016 to get a better understanding of what you’re currently doing and what you’ll be required to do by the QMSR.

Cue the applause, because the medical device industry has been buzzing about harmonization between FDA’s QSR and ISO 13485 since 2018 and now it’s finally happening.

While you’re thinking about the changes you need to make to comply with the QMSR, it also makes sense to take a step back and look at the QMS solution you’re using.

That’s why the agency is introducing a new labeling and packaging clause to the proposed Part 820.

There will also be at least a one-year period between the finalization of the rule and its implementation. That means December 2024 is the earliest the QMSR could go into effect. Still, this is a major step toward harmonization, and one that medical device professionals have long been waiting for.

The FDA states it is “proposing additional definitions, clarifying concepts, and additional requirements, all of which would require compliance within a manufacturer’s QMS in addition to ISO 13485.”

If you answered no to any of those questions, it’s probably time to modernize your QMS.

The FDA also notes that it has paid attention to the revisions to ISO 13485 over the years, and the agency feels the 2016 version of the standard is closely aligned with requirements of 21 CFR Part 820. All ISO standards are reviewed every five years to decide whether they need updating. The current version of ISO 13485 was last confirmed in 2020.

It’s a good idea to keep an eye on this proposed rule and any revisions that may occur prior to December 00. But this shouldn’t result in a total overhaul of your QMS. This harmonization is more about making life easier for everyone.

On Feb. 23, 2022, the U.S. Food and Drug Administration (FDA) released its proposed rule for the new Quality Management System Regulation (QMSR). The proposed QMSR will be the result of aligning the current good manufacturing practice (cGMP) requirements of the FDA’s Quality System Regulation (QSR) with the international consensus standard for medical device quality management systems, ISO 13485:2016.

With that said, there are a few things to keep in mind regarding the proposed rule to harmonize the FDA QSR with ISO 13485:2016:
• Once the rule is finalized, there will be a one-year waiting period before it goes into effect.
• The proposed rule may also result in changes to the current Quality System Inspection Technique (QSIT) to make it consistent with the new QMSR requirements.
• The FDA is proposing to harmonize the QSR with ISO 13485:2016, which is the latest version of the ISO standard. Any future revision to ISO 13485 would first need to be evaluated by the FDA before being incorporated into the QMSR.
• Just because the QMSR will be harmonized with ISO 13485 doesn’t mean you’ll be issued an ISO 13485 certification of conformance after an inspection. Likewise, if you already are ISO 13485-certified, that won’t exempt you from FDA inspections.

How can medtech companies prepare for the QMSR?

So please consider turning off your ad blocker for our site.

Although ISO 13485 has been revised repeatedly over the past two decades, the QSR remains nearly unchanged since it was released in 1996.

As such, it makes sense for the FDA to harmonize the two and eliminate the redundancy and inefficiency that many medical device companies face while attempting to satisfy the requirements of both the QSR and ISO 13485.

December 2024 will be here sooner than you think, so it’s worth it to start looking at your current labeling and packaging procedures now and start getting them in line with what will be expected.

Why is the FDA proposing this harmonization?

Is it built specifically for medtech? Does it help you achieve truly paperless audits? Does it come with a top-notch team of medical device experts who are always ready to help?

On the other hand, there are terms and definitions in ISO 13485 that “would create inconsistencies with the Federal Food Drug & Cosmetic Act and its implementing regulations.” In these cases, the FDA’s definitions will supersede those of ISO 13485. For example, device and labeling will supersede the definitions for medical device and labeling in ISO 13485.

At Greenlight Guru, we understand that risk management is a fundamental aspect of the entire medical device life cycle, which is why we built Risk Solutions, a first-of-its-kind, complete risk management software for medtech companies.

However, someone has to pay for this content. And that’s where advertising comes in. Most people consider ads a nuisance, but they do serve a useful function besides allowing media companies to stay afloat. They keep you aware of new products and services relevant to your industry. All ads in Quality Digest apply directly to products and services that most of our readers need. You won’t see automobile or health supplement ads.

December 2024 might sound like it’s pretty far off today, but that actually makes this the perfect time to begin thinking about how you’ll get compliant with the QMSR.

The FDA repeatedly mentions in its proposed rule that the QMS requirements in Part 820 and ISO 13485 are substantially similar: “Where ISO 13485 diverges from the current Part 820, these differences are generally consistent with the overall intent and purposes behind FDA’s regulation of QMSs.”

The FDA notes that it expects manufacturers to integrate risk management activities throughout their QMS and across the product life cycle. But they also acknowledge that ISO 13485 more explicitly establishes those requirements. Incorporating ISO 13485 by reference will ensure that the new QMSR has a more overt stance on the importance of risk management in design controls.

Quality Digest does not charge readers for its content. We believe that industry news is important for you to do your job, and Quality Digest supports businesses of all types.

The good news is, many of these changes are semantic in nature and don’t change the basic QMS requirements for medical device companies. For instance, you’ll notice that the term device master record is nixed under the current proposal because it isn’t used in ISO 13485, and the concept behind it is adequately covered in ISO 13485’s requirement for a medical device file.

While this may seem like a lot of change for medical device manufacturers, it’s important to keep in mind that the FDA already believes ISO 13485 to be substantially similar to the current QSR.

The FDA also estimates that harmonization will save medical device companies at least $439 million during the next decade by reducing the compliance burden on medical device companies that currently have to comply with both standards.

What does the FDA QSR transition to ISO 13485 mean for medical device manufacturers?

Customer Care

What FDA QSR and ISO 13485 Harmonization Means

QMSR for medical device companies

So, let’s cut to the chase: Why is the FDA harmonizing the standards, what do the new changes look like, and what will these changes mean for medical device companies?

How does the QMSR differ from the QSR?

It’s a good idea to become familiar with these sections of the QMSR now and consider how you’ll achieve compliance with their requirements, even if you’re currently in conformity with ISO 13485:2016.

Thanks,
Quality Digest